Biochem/physiol Actions

Target IC₅₀: 18 µM against angiotensin converting enzyme

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Primary TargetMMPs

General description

A hydroxamate-based inhibitor of matrix metalloproteinases and TACE (TNF-α convertase; ADAM17). Inhibits the activation-dependent shedding of L-selectin from neutrophils, eosinophils, and lymphocytes as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also blocks the shedding of several cell surface proteins such as pro-TGF-α, IL-6 receptor α-subunit, and β-amyloid precursor protein. Reported to inhibit TNF-α release and impart protection against aspirin-induced gastric mucosal injury. Acts as a weak inhibitor of angiotensin converting enzyme (IC₅₀ = 18 µM).

A hydroxamate-based inhibitor of MMPs and TACE. Inhibits the activation-induced shedding of L-selectin from neutrophils, eosinophils, and lymphocytes, as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also acts as a weak inhibitor of angiotensin converting enzyme (IC₅₀ = 18 µM). Also available as a 10 mM solution in H₂O (Cat. No. 509612).

Legal Information

Manufactured exclusively by Peptides International, Louisville, Kentucky, USA.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Bennett, T.A., et al. 2000. J. Immunol.164, 4120.Fiorucci, S., et al. 1998. Aliment. Pharmacol. Ther.12, 1139.Hooper, N.M., et al. 1997. Biochem. J.321, 265.Parvathy, S., et al. 1997. Biochem. J. 327, 37.Arribas, J., et al. 1996. J. Biol. Chem.271, 11376.

Packaging

1 mg in Plastic ampoule

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)